The current coronavirus pandemic is an ongoing global health crisis due to COVID-19,
caused by severe acute respiratory syndrome coronavirus 2. Although COVID-19 leads to …

Therapeutic drug monitoring (TDM) of biologics is a rapidly evolving field. We aimed to
provide a consensus statement regarding the clinical utility of TDM for biologics in …

COVID-19 is a pandemic caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2). Early reported symptoms include fever, cough, and respiratory symptoms …

Background AJM300 is an oral, small-molecule α4-integrin antagonist. We assessed the
efficacy and safety of AJM300 in patients with moderately active ulcerative colitis. Methods …

Background & Aims Safety is a key consideration when choosing advanced therapies
(biologic agents and oral small-molecule inhibitors/modulators) in patients with inflammatory …

Inflammatory bowel diseases (IBD), comprising Crohn disease (CD) and ulcerative colitis
(UC), are chronic inflammatory conditions of the gastrointestinal tract driven by inappropriate …

The incidence and prevalence of Crohn's disease (CD) is rising globally. Patients with
moderate to severe CD are at high risk for needing surgery and hospitalization and for …

The burden of inflammatory bowel disease (IBD) in older adults (ie, aged over 60 years old)
is increasing due to a combination of an ageing population with compounding prevalence of …

A subset of patients with ulcerative colitis (UC) present with, or progress to, moderate to
severe disease activity. These patients are at high risk for colectomy, hospitalization …

Inflammatory bowel diseases (IBDs) are increasingly common diseases characterized by
chronic and relapsing inflammation of the gastrointestinal tract. NLRP3 might be a crucial …